Particulate systems for targeting of macrophages: Basic and therapeutic concepts

Journal of Innate Immunity

Volumn 4, Issue 5-6, 2012, Pages 509-528

  Moghimi, S M ^a   Parhamifar, L ^a   Ahmadvand, D ^a   Wibroe, P P ^a   Andresen, T L ^b   Farhangrazi, Z S ^c   Hunter, A C ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c Nikkia Biosystems Inc   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Drug delivery; Macrophage diseases; Nanomedicine; Nanoparticles; Phagocytosis

Indexed keywords

DRUG CARRIER; LIPOSOME; NANOPARTICLE;

CELL SUBPOPULATION; CHEMICAL COMPOSITION; CYTOLOGY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; HYDRODYNAMICS; IMMUNOCOMPETENT CELL; KUPFFER CELL; MACROPHAGE; MACROPHAGE FUNCTION; MICELLE; MONOCYTE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; TARGET CELL;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MACROPHAGES; MICE; NANOPARTICLES; NANOTECHNOLOGY; PHAGOCYTOSIS; RABBITS; RATS;

EID: 84866041533     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000339153     Document Type: Review

References (117)

1. Gordon S (ed): The Macrophage as Therapeutic Target. Berlin, Springer, 2003, vol 158.
2. Moghimi SM, Hunter AC, Murray JC: Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001; 53: 283-318. (Pubitemid 32476118)
3. Moghimi SM, Hunter AC, Murray JC: Nano-medicine: current progress and future prospects. FASEB J 2005; 19: 311-330. (Pubitemid 40316520)
4. Taylor PR, Martinez-Pomarez L, Stacey M, et al: Macrophage receptors and immune recognition. Ann Rev Immunol 2005; 23: 901-944. (Pubitemid 40563189)
5. Sleyster EC, Knook DL: Relation between localization and function of rat liver Kupffer cells. Lab Invest 1982; 47:484-490. (Pubitemid 13229687)
6. Winkler GC: Pulmonary intravascular mac-rophages in domestic animal species: review of structural and functional properties. Am J Anat 1988; 181:217-234.
7. Moghimi SM: Exploiting bone marrow mi-crovascular structure for drug delivery and future therapies. Adv Drug Deliv Rev 1995; 17:61-73.
8. Porter CJH, Moghimi SM, Illum L, et al: The polyoxyethylene/ polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett 1992; 305: 62-66.
9. Hobbs SK, Monsky WL, Yuan F, et al: Regulation of transport pathways in tumor vessels: role of tumor type and microenviron-ment. Proc Natl Acad Sci USA 1998; 95: 4604-4612.
10. Munn LL: Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 2003; 8: 396-403. (Pubitemid 36442691)
11. Abu-Hijleh MF, Habbal OA, Moqattash ST: The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J Anat 1995; 186: 453-467.
12. Miura T, Shimada T, Tanaka K, et al: Lymphatic drainage of carbon particles injected into the pleural cavity of the monkey as studied by video-assisted thoracoscopy and electron microscopy. J Thorac Cardiovasc Surg 2000; 120:437-447.
13. Moghimi SM: Nanoparticle engineering for the lymphatic system and lymph node targeting; in Broz P. (ed): Polymer-Based Nano-structures: Medical Applications. Cambridge, Royal Society of Chemistry, 2010, pp 81-97.
14. Moghimi SM, Rajabi-Siahboomi AR: Advanced colloid-based systems for efficient delivery of drugs and diagnostic agents to the lymphatic tissues. Prog Biophys Mol Biol 1996; 65: 221-249. (Pubitemid 27164027)
15. Reddy ST, van der Vlies AJ, Simenoi E, et al: Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007; 25:1159-1164. (Pubitemid 47538111)
16. Moghimi SM: The innate immune responses, adjuvants and delivery systems; in Jor-gensen L, Nielsen HM (eds): Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines. Chich-ester, John Wiley & Sons, 2009, pp 113-127.
17. Tilg H, Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-783. (Pubitemid 44453463)
18. Knight SC: Specialized perinodal fat fuels and fashions immunity. Immunity 2008; 28: 135-138. (Pubitemid 351215230)
19. Viallat RT, Raybuad F, Passarel M, et al: Pleu-ral migration of chrysotile fibers after intra-tracheal injection in rats. Arch Environ Hea lth 1986; 41: 282-286. (Pubitemid 17001855)
20. Mowat AM, Bain CC: Mucosal macrophages in intestinal homeostasis and inflammation. J Innate Immun 2011;3:550-564.
21. Moghimi SM, Hunter AC, Andresen TL: Factors controlling nanoparticle pharmaco-kinetics: an integrated approach and perspective. Annu Rev Pharmacol Toxicol 2012; 52:481-503.
22. Monopoli MP, Walczyk D, Campbell A, et al: Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 2011; 133: 2525-2534.
23. Hamad I, Al-Hanbali O, Hunter AC, et al: Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 2010;4:6629-6638.
24. Moghimi SM, Andersen AJ, Ahmadvand D, et al: Material properties in complement activation. Adv Drug Deliv Rev 2011; 63:1000-1007.
25. Sou K, Goins B, Takeoka S, et al: Selective uptake of surface-modified vesicles by bone marrow macrophages in vivo. Biomaterials 2006; 28:2655-2666.
26. Moghimi SM: Recent developments in polymeric nanopartricle engineering and their applications in experimental and clinical oncology. Anticancer Agent Med Chem 2006; 6: 553-561.
27. Moghimi SM, Muir IS, Illum L, et al: Coating particles with a block co-polymer (polox-amine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta-Mol Cell Res 1993; 1179: 157-165. (Pubitemid 23328718)
28. Moghimi SM, Szebeni J: Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003; 42:463-478. (Pubitemid 37237636)
29. Moghimi SM, Hamad I, Andresen TL, et al: Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene gly-col) conjugate prevents PEGylated liposome-mediated complement activation and ana-phylatoxin production. FASEB J 2006; 20: 2591-2593.
30. Moghimi SM, Hunter AC: Complement monitoring of carbon nanotubes. Nat Nano-technol 2010; 5:382.
31. Moghimi SM, Porter CJH, Muir IS, et al: Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Bio-chem Biophys Res Commun 1991; 177:861-866.
32. Moghimi SM: Mechanisms of splenic clearance of blood cells and particles: towards development of new splenotropic agents. Adv Drug Deliv Rev 1995; 17:103-115.
33. Moghimi SM, Hedeman IS, Muir IS, et al: An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim Biophys Acta-Mol Cell Res 1993; 1157:233-240. (Pubitemid 23207804)
34. Moghimi SM, Hedeman H, Illum L, et al: Effect of splenic congestion associated with haemolytic anaemia on filtration of 'spleen-homing' microspheres. Clin Sci (Lond) 1993; 84:605-609. (Pubitemid 23171169)
35. Moghimi SM: Modulation of lymphatic distribution of subcutaneously injected polox-amer 407-coated nanospheres: the effect of the ethylene oxide chain configuration. FEBS Lett 2003; 540: 241-244. (Pubitemid 36398064)
36. Moghimi SM: The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG lipo-somes. Biomaterials 2006; 27: 136-144. (Pubitemid 41225377)
37. Moghimi SM, Moghimi M: Enhanced lymph node retention of subcutaneously injected IgG1-PEG2000-liposomes through pentam-eric IgM antibody-mediated vesicular aggregation. Biochim Biophys Acta-Biomemb 2008; 1778: 51-55.
38. Jain R, Dandekar P, Patravale V: Diagnostic nanocarriers for sentinel lymph node imaging. J Control Release 2009; 138: 90-102.
39. Champion JA, Mitragotri S: Role of target geometry in phagocytosis. Proc Natl Acad Sci USA 2006; 103:4930-4934.
40. Yoo JW, Mitragotri S: Polymer particles that switch shape in response to a stimulus. Proc Natl Acad Sci USA 2010; 107:11205-11210.
41. Ruggiero A, Villa CH, Bander E, et al: Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci USA 2010; 107:12369-12374.
42. Geng Y, Dalhaimer P, Cai S, et al: Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2007; 2:249-255. (Pubitemid 46739812)
43. Agrawal AK, Gupta CM: Tuftsin-bearing li-posomes in treatment of macrophage-based infections. Adv Drug Deliv Rev 2000; 41: 135-146. (Pubitemid 30122954)
44. Kristiansen M, Graversen JH, Jacobsen C, et al: Identification of the hemoglobin scavenger receptor. Nature 2002; 409: 198-201.
45. Buechler C, Ritter M, Orso E, et al: Regulation of the scavenger receptor CD163 expression in human monocytes and macrophages by pro-and anti-inflammatory stimuli. J Leukoc Biol 2000; 67:97-103. (Pubitemid 30046823)
46. Etzerodt A, Maniecki MB, Graversen JH, et al: Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J Control Release 2012, DOI: 10.1016/j.jconrel.2012. 01.034.
47. Royer PJ, Emara M, Yang C, et al: The man-nose receptor mediates the uptake of diverse native allergens by dendritic cells and determines allergen-induced T cell polarization through modulation of IDO activity. J Immunol 2010; 185: 1522-1531.
48. Gazi U, Martinez-Pomares L: Influence of the mannose receptor in host immune responses. Immunobiol 2009; 214:554-561.
49. Schenk GJ, Haasnoot PCJ, Centlivre M, et al: Efficient CRM197-mediated drug targeting to monocytes. J Control Release 2012; 158: 139-147.
50. Moghimi M, Moghimi SM: Lymphatic targeting of immuno-PEG-liposomes: evaluation of antibody-coupling procedures on lymph node macrophage uptake. J Drug Target 2008; 16: 586-590.
51. Gupta S, Pal A, Vyas SP: Drug delivery strategies for therapy of visceral leishmaniasis. Expt Opin Drug Deliv 2010; 7:371-402.
52. Griffiths G, Nystroem B, Sable SB, et al: Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol 2010; 8:827-834.
53. Drummond DC, Zignani M, Leroux JC: Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res 2000; 39:409-460.
54. Yoo JW, Irvine DJ, Discher DE, et al: Bio-inspired bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 2011; 10: 521-535.
55. 8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigens and poly(inosinic acid)-poly(cytidylic acid). Bio-materials 2009; 30:910-918.
56. Gibaud S, Weingarten C, Andreux JP, et al: Targeting bone marrow with the help of polyalkylcyanoacrylate nanoparticles. Ann Pharm Fr 1999; 57: 324-331. (Pubitemid 29376322)
57. Scholer N, Hahn H, Muller RH, et al: Effect of lipid matrix and size of solid lipid nanopar-ticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 2002; 231: 167-176. (Pubitemid 34033676)
58. Elferink JG: Cytolytic effect of polylysine on rabbit polymorphonuclear leukocytes. Inf lammation 1985; 9: 321-331. (Pubitemid 16247492)
59. Chellat F, Merhi Y, Moreau A, et al: Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials 2005; 26: 7260-7275. (Pubitemid 41133578)
60. Pinto-Alphandary H, Balland O, Laurent M, et al: Intracellular visualization of ampicil-lin-loaded nanoparticles in peritoneal mac-rophages infected in vitro with Salmonella typhimurium. Pharm Res 1994; 11:38-46. (Pubitemid 24040761)
61. Forestier F, Gerrier P, Chaumard C, et al: Effect of nanoparticle-bound a mpicillin on the survival of Listeria monocytogenes in mouse peritoneal macrophages. J Antimicrob Che-mother 1992; 30:173-179.
62. Symonds P, Murray C, Hunter AC, et al: Low and high molecular weight poly(L-lysine)s/poly(L-lysine)-DNA complexes initiate mi-tochondrial-mediated apoptosis differently. FEBS Lett 2005; 579: 6191-6198. (Pubitemid 41546267)
63. Moghimi SM, Symonds P, Murray JC, et al: A two-staged poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther 2005; 11: 990-995. (Pubitemid 40724119)
64. Moghimi SM, Hunter AC, Murray JC, et al: Cellular distribution of micelles. Science 2004; 303: 626-627.
65. Parhamifar L, Larsen AK, Hunter AC, et al: Polycation cytotoxicity: a delicate matter for nucleic acid therapy-Focus on polyethyleni-mine. Soft Matt 2010; 6:4001-4009.
66. Kirkeggard T, Jaattela M: Lysosoma l involvement in cell death and cancer. Biochim Bio-phys Acta-Mol Cell Res 2009; 1793:746-754.
67. Stoka V, Turk B, Schendel SL, et al: Lysosom-al protease pathway to apoptosis: cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem 2001; 276: 3149-3157.
68. Stoka V, Turk V, Turk B: Lysosomal cysteine cathepsins: signalling pathways in apoptosis. Biol Chem 2007; 388:555-560. (Pubitemid 46883446)
69. Daemen T, Hofstede G, Kate MTT, et al: Li-posomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer 1995; 61: 716-721.
70. Dale GL, Kuhl W, Beutler E: Incorporation of glucocerebrosidase into Gaucher's disease monocytes in vitro. Proc Natl Acad Sci USA 1979; 76:473-475. (Pubitemid 9110220)
71. Belchetz PE, Crawley JC, Braidman IP, et al: Treatment of Guacher's disease with lipo-some entrapped glucocerebroside beta-glu-cosidase. Lancet 1977; 2:116-117. (Pubitemid 8124949)
72. Balicki D, Beutler E: Gene therapy of human disease. Medicine 2002; 81: 69-86.
73. Inoue K, Lupski JR: Molecular mechanisms for genomic disorders. Ann Rev Genom Hum Genet 2002; 3: 199-242. (Pubitemid 35217436)
74. Ebert RH, Florey HW: The extravascular development of the monocyte observed in vivo. Brit J Exp Pathol 1939; 20:342-356.
75. Gordon S, Taylor PR: Monocyte and macro-phage heterogeneity. Nat Rev Immunol 2005; 5: 953-964.
76. Block ML, Zecca L, Hong JS: Microglia-me-diated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8: 57-69. (Pubitemid 46011999)
77. + monocytes only under defined host conditions. Nature Neurosci 2007; 10: 1544-1553. (Pubitemid 350175884)
78. Dou HY, Grotepas CB, McMillan JM, et al: Macrophage delivery of nanoformulated an-tiretroviral drug to the brain in a murine model of neuroA IDS. J Immunol 2009; 183: 661-669.
79. Aouadi M, Tesz GJ, Nicoloro SM, et al: Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009; 458:1180-1184.
80. Kraal G, van Rooijen N: Reaching the mac-rophage: routes of delivery; in Gordon S (ed): The Macrophage as Therapeutic Target. Berlin, Springer, 2003, vol 158, pp 55-65.
81. van Lent PLEM, Krijger GC, Hofkens W, et al: Selectively induced death of macrophages in the synovial lining of murine knee joints using B-10-liposomes and boron neutron capture synovectomy. Int J Rad Biol 2009; 85: 860-871.
82. Hirsch LR, Gobin AM, Lowery AR, et al: Metal nanoshells. Ann Biomed Engineering 2006; 34: 15-22.
83. Hirsch LR, Stafford RJ, Bankson JA, et al: Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 2003; 100: 13549-13554. (Pubitemid 37444779)
84. 64 Cu loaded liposomes as positron emission tomography imaging agents. Biomaterials 2011; 32: 2334-2341.
85. Moghimi SM, Bonnemain B: Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: aplications in lymphoscintigraphy and indirect lym-phography. Adv Drug Deliv Rev 1999; 37: 295-312. (Pubitemid 29164514)
86. Kim S, Lim YT, Soltesz, et al: Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 2004; 22: 93-97. (Pubitemid 38057962)
87. Maysinger D, Lovric J, Eisenberg A, et al: Fate of micelles and quantum dots in cells. Eur J Pharm Biopharm 2007; 65:270-281.
88. Derfus AM, Chan WCW, Bhatia SN: Probing the cytotoxicity of semiconductor quantum dots. Nano Lett 2004; 4:11-18. (Pubitemid 38167855)
89. Al-Hajaj, Moquin A, Neibert KD, et al: Short ligands affect modes of QD uptake and elimination in human cells. ACS Nano 2011; 5: 4909-4918.
90. Neibert KD, Maysinger D: Mechanisms of cellular adaptation to quantum dots-the role of glutathione and transcription factor EB. Nanotoxicology 2012; 6:249-262.
91. Gordon S: Alternative activation of macro-phages. Nat Rev Immunol 2003; 3: 23-35.
92. Wilson HM: Macrophage heterogeneity in atherosclerosis-implications for therapy. J Cell Mol Med 2010; 14:2055-2065.
93. Stoger JL, Goossens P, de Winther MPJ: Mac-rophage heterogeneity: relevance and functional implications in atherosclerosis. Curr Vascula r Pharmacol 2010; 8: 233-248.
94. Kim WK, Sun Y, Do H, et al: Monocyte heterogeneity underlying phenotypic changes in monocyte according to SIV disease stage. J Leukoc Biol 2010; 87:557-567.
95. Ghosn EEB, Cassado AA, Govoni GR, et al: Two physically, functionally, and develop-mentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci USA 2010; 107: 2568-2573.
96. Martinez FO, Gordon S, Locati M, et al: Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006; 176:7303-7311. (Pubitemid 44715100)
97. Hagemann T, Wilson J, Burke F, et al: Ovarian cancer cells polarize macrophage towards a tumor-associated phenotype. J Immunol 2006; 176:5023-5032.
98. Mebius RE, Kraal G: Structure and function of the spleen. Nat Rev Immunol 2005; 5:606-616. (Pubitemid 41113192)
99. Tomita M, Yamamoto, K, Kobashi H, et al: Immunohistochemical phenotyping of liver macrophages in normal and diseased human liver. Hepatology 1994; 20:317-325. (Pubitemid 24233355)
100. Hoedemakers RMJ, Morselt HWM, Scherp-hof GL, et al: Secretion pattern of the rat-liver macrophage population following activation with liposomal muramyl dipeptide in-vivo and in-vitro. J Immunother 1994; 15: 265-272.
101. Moghimi SM, Hedeman H, Christy NM, et al: Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats. J Leukoc Biol 1993; 54:513-517. (Pubitemid 24024219)
102. Moghimi SM, Murray JC: Poloxamer-188 revisited: a potentially valuable immune modulator? J Natl Cancer Inst 1996; 88:766-768. (Pubitemid 26195027)
103. Moghimi SM, Gray T: A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macro-phage clearance of subsequent doses in rats. Clin Sci (Lond) 1997; 93: 371-379. (Pubitemid 27464301)
104. Moghimi SM, Patel HM: Modulation of murine liver macrophage clearance of lipo-somes by diethylstilbestrol: the effect of vesicle surface charge and a role for the complement receptor Mac-1 (CD11b/CD18) of newly recruited macrophages in lipo-some recognition. J Control Release 2002; 78:55-65. (Pubitemid 34081853)
105. Hotta C, Fujimaki H, Yoshinari M, et al: The delivery of an antigen from the endo-cytic compartment into the cytosol for cross-presentation is restricted to early immature dendritic cells. Immunology 2006; 117:97-107.
106. Tran KK, Shon H: The role of phagosomal pH on the size-dependent efficiency of cross-presentation by dendritic cells. Bio-materials 2009; 7:1356-1362.
107. Kubo M, Hanada T, Yoshimura A: Suppres-sors of cytokine signaling and immunity. Nat Immunol 2003; 4: 1169-1176.
108. Benjaminsen RV, Sun H, Henriksen JR, et al: Evaluating nanoparticle sensor design for intracellular pH measurement. ACS Nano 2011; 5: 5864-5873.
109. Pramod Kumar EK, Almdal K, Andresen TL: Synthesis and characterization of ratio-materic nanosensors for pH quantification: a mixed micelle approach. Chem Commun (Camb) 2012; 18: 4776-4778.
110. Sokurenko EV, Vogel V, Thomas WE: Catch-bond mechanism of force-induced adhesion: counterintuitive, elusive, but widespread? Cell Host Microbe 2008; 16: 314-323.
111. TM)-induced complement activation in human sera: a protective role against poloxamer-mediated complement activation by elevated levels of lipo-proteins. Biochim Biophys Acta 2004; 1689: 103-113. (Pubitemid 38766145)
112. Moghimi SM, Andersen AJ, Hashemi SH, et al: Complement activation cascade triggered by PEG-PL engineered nanomedi-cines and carbon nanotubes: the challenges ahead. J Control Release 2010; 146: 175-181.
113. Szebeni J, Muggia F, Gabizon A, et al: Activation of complement by therapeutic lipo-somes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011; 63: 1020-1030.
114. TM nanoparticles. J Control Release 2007; 121:10-18. (Pubitemid 47126067)
115. Doshi N, Swiston AJ, Gilbert JB, et al: Cell-based drug delivery devices using phagocytosis-resistant backpacks. Adv Mat 2011; 23:H105-H109.
116. Moghimi SM, Illum L, Davis SS: Physio-pathological and physicochemical considerations in targeting of colloids and drug carriers to the bone marrow. Crit Rev Ther Drug Carr Syst 1990; 7:187-209.
117. Jolk RI, Feldborg LN, Andersen S, et al: Engineering liposomes and nanoparticles for biological targeting. Adv Biochem Engin Biotechnol 2011; 125: 251-280.